- ADMA Biologics recently reported its Q3 earnings with a beat on EPS and revenue. In addition, the company reported encouraging commercial progress for its IVIG products despite the COVID-19 headwinds.
- Unfortunately, the healthcare sector is experiencing some selling pressure after the outcome of the U.S. presidential election, and ADMA is moving closer to 52-week lows.
- I intended to take advantage of the unjustified sell-off and will explain my reasoning for buying into the weakness.
For further details see:
ADMA Biologics: Another Quarter Of Progress And Another Dip To Buy